Publications
Dec 1, 2024
Advancing Together
We partner with laboratory veterinarians and research teams to deliver tailored pain management, comprehensive data access, and collaborative opportunities that advance scientific knowledge through joint research and publications.
Preclinical Research Partnerships
Ethiqa XR can be integrated into your post-procedural pain management.
Access to Industry Thought Leaders
Our team includes industry experts and veterinarians ready to answer any of your questions.
Support for Experimental Protocols
Our experts assist with protocol development to ensure compliance, reduce animal stress, and optimize pain management outcomes.
Co-Authorship & Publication Opportunities
Partner with us to share your findings and contribute to advancing veterinary analgesia in laboratory species.
Essential Resources for Lab Researchers
Our curated library of published safety and PK studies, and handling guidelines are designed to help you confidently incorporate Ethiqa XR into your laboratory animal care and research programs.
From detailed pharmacology to practical administration advice, our resources support your research and animal welfare goals with clarity and full regulatory compliance.
Tailored Relief Across Species
Ethiqa XR is formulated to meet the unique pain management needs for post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. Its long-lasting relief and strong safety record give veterinarians and researchers confidence to provide effective, species-appropriate care tailored for each animal’s well-being.
- Captive Rodents
- Ferrets
- Laboratory Rabbits
- Non-Human Primates
Ethiqa XR is FDA-indexed for the control of post-procedural pain for Captive Rodents
Ethiqa XR is FDA-indicated for post-procedural pain in captive rodents like mice and rats. One injection provides up to 72 hours of steady relief and reduces stress. Safety studies confirm it’s well tolerated, making it ideal for humane care in research.
Extended Comfort for Ferrets
For ferrets, Ethiqa XR provides effective pain relief after surgery. It reaches therapeutic blood levels quickly and maintains them for up to 72 hours. This sustained relief supports smoother, less stressful recoveries, improving comfort and welfare in research settings.
Reliable Analgesia for Laboratory Rabbits
Ethiqa XR delivers consistent, long-lasting pain relief for laboratory rabbits with a single injection lasting up to 72 hours. Its strong safety profile makes it a trusted option, supporting humane, effective pain management during research procedures involving laboratory rabbits.
Safe Relief for Non-Human Primates
Ethiqa XR offers extended pain control in non-human primates with a single injection. It maintains therapeutic blood levels for up to 72 hours. Studies report no adverse effects or abnormal behaviors, supporting its safe, reliable use in primate research care.
Thorough Standards, Reliable Compliance
Ethiqa XR is FDA-indexed for control of post-procedural paint in captive rodents, ferrets, laboratory rabbits, and non-human primates. Manufactured under cGMP and complies with DEA regulations, Ethiqa XR ensures quality, transparency, and regulatory compliance for your research facility.
Ethiqa XR supports your compliance needs and helps maintain the highest standards in laboratory animal pain management protocols.
-
FDA-Indexed for Veterinary Use
-
DEA & cGMP Standards
Produced under controlled substance and manufacturing regulations.
-
Pharmacovigilance
Strict monitoring and reporting of adverse events to comply with FDA pharmacovigilance regulations. Product complaints are also strictly monitored and investigated, and complies with FDA regulations.
-
CGMP compliant
FAQ
We’ve answered some of the most common questions about Ethiqa XR’s use, safety, and support.
See All FAQs
What is the NDC number for Ethiqa XR?
The NDC number is 86084-100-30.
How long is analgesia shown to last?
In the pharmacokinetic studies, therapeutic drug concentrations of Ethiqa XR were maintained for up to 72 hours post-injection in captive rodents, ferrets, laboratory rabbits, and non-human primates.
Does Ethiqa XR require refrigeration?
Ethiqa XR does not require refrigeration and should be stored at room temperature, specifically between 15° to 25°C +/- 2°C (59°F to 77°F). If Ethiqa XR has been refrigerated, it should be allowed to reach room temperature before use. Do not heat Ethiqa XR. Heating the product or not storing the product in its original container or within the specified storage conditions could cause the product to change its physical properties.
For what species is Ethiqa XR indicated?
Ethiqa XR is indicated for control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. See the Package Insert, including Boxed Warning, for additional details.
What is the return policy?
Ethiqa XR is a controlled drug substance (CIII) and is generally not returnable; however, the return policy is determined by the distributor. For additional information, please contact your distributor.
Supporting Research Through Science-Based Resources
We’re Here to Support You
Your insights matter—because animal care starts with true collaboration. Ethiqa XR is a trusted, science-backed product for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. We are here to support you every step of the way. Connect with our team, ask questions, and stay informed. Together, we’re advancing animal welfare and raising the standard of care.
Contact Us
Real peopleproviding dedicated support
Direct access to experienced veterinary experts
Backed by thorough, proven research data.
ETH.LP.203.01.D.ALL.AL
Boxed Warning
Abuse Potential
ETHIQA XR contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ETHIQA XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g., depression).
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ETHIQA XR. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.
Accidental Exposure
Because of the potential for adverse reactions associated with accidental exposure, ETHIQA XR should only be administered by veterinarians, veterinary technicians, or laboratory staff who are trained in the handling of potent opioids. Accidental exposure to ETHIQA XR, especially in children, can result in a fatal overdose of buprenorphine.
Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants
Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
See HUMAN SAFETY WARNINGS for detailed information.
Important Safety Information
For Captive Rodents, Ferrets, Laboratory Rabbits, and Non-Human Primates:
Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.
Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiqa XR have been administered concomitantly in mice.
Do not house rats on wood chip-type bedding after administration of Ethiqa XR. Pica involving wood chip type bedding can be lethal.
Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR.
The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.
For Humans:
Not for use in humans. Keep out of reach of children and pets.
Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.
Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.
Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.
For more information, consult the Prescribing Information including the Boxed Warning.
SA.EthiqaXR.060.05.2024